imatinib mesylate has been researched along with Benign Cranial Nerve Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akgün, E; Avsar, T; Bayri, Y; Kılıç, T; Şeker, A; Yener, U | 1 |
1 other study(ies) available for imatinib mesylate and Benign Cranial Nerve Neoplasms
| Article | Year |
|---|---|
Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain; Cornea; Cranial Nerve Neoplasms; Glioblastoma; Humans; Imatinib Mesylate; Male; Neovascularization, Pathologic; Neurofibromatosis 2; Neuroma, Acoustic; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |